Demographic and Baseline Characteristics A. Demographic data DIMS0150 Placebo    (n=12) (n=22) Gender Male 12 (54.5%) 6 (50.0%)   Female 10 (45.4%) 6 (50.0%) Race Caucasian 22 (100.0%) 12 (100.0%) Age (years) Mean (SD) 41.3 (15.0) 39.7 (12.4)   Min, Max 23.0, 72.0 22.0, 56.0 B. Baseline Characteristics DIMS0150 Placebo (n=22) (n=12) Disease duration (years) Nr of patients 16 7   Missing 6 5   Mean (SD) 2.5 (2.3) 4.8 (2.2)   (Min, Max) (0.4, 9.7) (2.5, 8.2) DAI score at screening Nr of patients 22 12   Mean (SD) 7.9 (1.2) 7.9 (1.5)   (Min, Max) 7.0, 10.0 6.0, 11.0 UC extent Beyond splenic flexure 3 (14%) 2 (17%)   Up to splenic flexure 10 (45%) 6 (50%)   Up to sigmoid descending junction 7 (32%) 3 (25%)   Up to recto-sigmoid junction 1 (4%) 1 (%)   Not known 1 (4%) 0 Concomitant glucocorticoids Nr of patients 20 (91%) 11 (92%)   Prednisolone 19 (86%) 10 (83%)   Budesonide 2 (9%) -   Methylprednisolone - 1 (8%) No concomitant glucocorticoids Nr of patients 2 1

Table 1: Demographic and baseline characteristics of patients; Summary of demographic and baseline characteristics of patients assigned into the study. The disease extent and concomitant steroid medication are also indicated. Disease duration could not be determined for all included subjects. Steroids medication that occur more than once during the study period will be counted only once within a subject. Percentage calculated for the number of subjects by treatment group.